CLBS12
- Generic Name
- CLBS12
- Drug Type
- Biotech
- Background
CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.
Critical Limb Ischemia Market Projected to Reach $2.5 Billion by 2035, Driven by Novel Therapies and Advanced Diagnostics
• The critical limb ischemia (CLI) market is expected to grow from $1.4 billion in 2024 to $2.5 billion by 2035, with a CAGR of 6.66%, fueled by advances in early detection technologies and personalized medicine approaches.
• Novel therapies in development include oxygen carriers (YQ23), autologous stem cell treatments (ASCT-01, CLBS12, ACP-01), and cell-based therapies (REX-001), all aimed at promoting angiogenesis and improving tissue perfusion in ischemic limbs.
• The United States represents the largest CLI market, with significant growth driven by FDA regulatory support through fast-track designations and regenerative medicine advanced therapy approvals for innovative treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath